Related Experiment Video
Updated: Oct 26, 2026
Thoracoscopic Extended Right Middle Plus Lower Sleeve Lobectomy for Non-Small-Cell Lung Cancer
Published on: February 27, 2026
Minimally invasive lobectomy following pathologic complete response to neoadjuvant Lorlatinib in ALK-positive
Alexandra Molkova1, Ruifeng Li1, Shuben Li2,1
1Department of Thoracic Surgery, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Abstract:
ALK rearrangements are uncommon in lung squamous cell carcinoma, and neoadjuvant ALK inhibition remains investigational. We report a 52-year-old never-smoking female with stage IIIB ALK-positive squamous cell carcinoma treated with neoadjuvant lorlatinib for 12 weeks. Serial imaging demonstrated a 61% reduction in tumor size with nodal regression. The patient subsequently underwent a uniportal video-assisted thoracoscopic (uVATS) lobectomy, and final pathology revealed a complete pathological response (pCR) of the primary tumor. This case highlights the feasibility and safety of minimally invasive anatomical lung resection following neoadjuvant lorlatinib despite treatment-related hilar fibrosis and vascular-bronchial adhesions.
